Emerging Paradigms in Cardiomyopathies Associated With Cancer Therapies
Key result
Targeted cancer therapies and angiogenesis inhibitors cause unexpected cardiovascular complications, including hypertension, thrombosis, and heart failure.
Population
Cancer patients
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports cardiac monitoring in targeted cancer therapy; extends cardio-oncology research priorities.
Structured PICO
P
Population
Cancer patients
E
Exposure
Cancer therapies, including traditional therapies (anthracyclines, radiation) and targeted therapies (kinase inhibitors, angiogenesis inhibitors)
O
Outcome
Cardiovascular complications (cardiomyopathies, hypertension, thrombosis, heart failure)
Both traditional and targeted cancer therapies can cause significant cardiovascular complications, highlighting the critical role of the emerging discipline of cardio-oncology.
Cite This Study
Ky et al. (2013) conducted a review in Cardiomyopathies associated with cancer therapies. Cancer therapies was evaluated. Targeted cancer therapies and angiogenesis inhibitors cause unexpected cardiovascular complications, including hypertension, thrombosis, and heart failure.